Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  2/11/2016
Woodlands Medical Specialists
mi
from
Pensacola, FL
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 2/11/2016
Woodlands Medical Specialists
mi
from
Pensacola, FL
Click here to add this to my saved trials
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  2/11/2016
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 2/11/2016
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  2/11/2016
St. Louis Cancer Care
mi
from
Chesterfield, MO
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 2/11/2016
St. Louis Cancer Care
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  2/11/2016
Portsmouth Regional Hospital
mi
from
Portsmouth, NH
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 2/11/2016
Portsmouth Regional Hospital
mi
from
Portsmouth, NH
Click here to add this to my saved trials
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  2/11/2016
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 2/11/2016
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Click here to add this to my saved trials
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  2/11/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 2/11/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant
Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/11/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant
Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/11/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation
Status: Enrolling
Updated:  2/12/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation
Status: Enrolling
Updated: 2/12/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  2/16/2016
Massachusetts General Hospital
mi
from
Boston, MA
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 2/16/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  2/16/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 2/16/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas
Status: Enrolling
Updated:  2/17/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas
Status: Enrolling
Updated: 2/17/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Augusta, GA
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Maywood, IL
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Maywood, IL
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Canton, OH
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Fort Meyers, FL
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Fort Meyers, FL
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Kansas City, KA
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Lexington, KY
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Paducah, KY
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Paducah, KY
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
St Louis, MO
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Morgantown, WV
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  2/17/2016
mi
from
Clayton,
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 2/17/2016
mi
from
Clayton,
Click here to add this to my saved trials
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas
Status: Enrolling
Updated:  2/17/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas
Status: Enrolling
Updated: 2/17/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Phase 2 Study of Planned Donor Lymphocyte Infusion After Reduced Intensity Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  2/18/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Phase 2 Study of Planned Donor Lymphocyte Infusion After Reduced Intensity Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 2/18/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
A Phase Ib/II Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Status: Enrolling
Updated:  2/19/2016
Cancer Treatment Center of America @ Western Regional Medical Center
mi
from
Goodyear, AZ
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
A Phase Ib/II Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Status: Enrolling
Updated: 2/19/2016
Cancer Treatment Center of America @ Western Regional Medical Center
mi
from
Goodyear, AZ
Click here to add this to my saved trials
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors.
Status: Enrolling
Updated:  2/20/2016
Sarah Cannon Cancer Center
mi
from
Nashville, TN
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors.
Status: Enrolling
Updated: 2/20/2016
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Status: Enrolling
Updated:  2/22/2016
Yale School of Medicine
mi
from
New Haven, CT
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Status: Enrolling
Updated: 2/22/2016
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Status: Enrolling
Updated:  2/22/2016
Memorial Cancer Institute
mi
from
Hollywood, FL
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Status: Enrolling
Updated: 2/22/2016
Memorial Cancer Institute
mi
from
Hollywood, FL
Click here to add this to my saved trials
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Status: Enrolling
Updated:  2/22/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Status: Enrolling
Updated: 2/22/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Status: Enrolling
Updated:  2/22/2016
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Status: Enrolling
Updated: 2/22/2016
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
University of Arkansas
mi
from
Little Rock, AR
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
University of Arkansas
mi
from
Little Rock, AR
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
City of Hope National Cancer Center
mi
from
Duarte, CA
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
City of Hope National Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
Mercy General Hospital
mi
from
Sacramento, CA
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
Mercy General Hospital
mi
from
Sacramento, CA
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
Georgetown University
mi
from
Washington,
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
Northwestern University
mi
from
Chicago, IL
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
North Shore University Hospital
mi
from
Manhasset, NY
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
West Virginia University
mi
from
Morgantown, WV
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
West Virginia University
mi
from
Morgantown, WV
Click here to add this to my saved trials
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  2/22/2016
Royal Adelaide Hospital
mi
from
Adelaide,
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 2/22/2016
Royal Adelaide Hospital
mi
from
Adelaide,
Click here to add this to my saved trials
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  2/23/2016
Stanford University
mi
from
Stanford, CA
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 2/23/2016
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  2/23/2016
Northwestern University Dept of Dermatology
mi
from
Chicago, IL
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 2/23/2016
Northwestern University Dept of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  2/23/2016
Cleveland Clinic
mi
from
Cleveland, OH
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 2/23/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  2/23/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 2/23/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  2/23/2016
Ohio State University
mi
from
Gahanna, OH
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 2/23/2016
Ohio State University
mi
from
Gahanna, OH
Click here to add this to my saved trials
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  2/23/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 2/23/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Statin Therapy in Young Adult Survivors of Childhood Cancer
Pilot Study of Statin Therapy in Young Adult Survivors of Childhood Cancer
Status: Enrolling
Updated:  2/24/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Statin Therapy in Young Adult Survivors of Childhood Cancer
Pilot Study of Statin Therapy in Young Adult Survivors of Childhood Cancer
Status: Enrolling
Updated: 2/24/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials